Gennex Laboratories (531739.BO) Stock Price

Gennex Laboratories Price

CLOSED
9.97
​
Market closed

Revenue has compounded at 12.0% per year over the past 18 years to 1.73 B INR. Earnings per share have grown at 16.7% per year over the last 18 years. Gennex Laboratories's net margin stands at 12.1%, up from 6.4% several years earlier.

Gennex Laboratories stock price

Access this data via the Eulerpool API

Gennex Laboratories business model & stock analysis

Gennex Laboratories Ltd. engages in the manufacture of bulk drugs and intermediates products. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the business of manufacturing bulk drugs, intermediaries, and biotech products. The firm has a robust product portfolio spread over major product segments encompassing expectorants, muscle relaxants, analgesic and anti-fungal. The firm operates through the Pharmaceutical Products (Bulk Drugs) segment. The firm's products include active pharmaceutical ingredients, such as Guaifenesin USP/BP/EP/IP, which is an expectorant, (mucolyte); Methocarbamol USP, which is a relaxant (skeletal muscle relaxant); Phenazopyridine Hcl USP, which is an urinary tract analgesic; Fluconazole EP/USP, which is an anti-fungal product; Mephenesin IP/BP, which is a muscle relaxant; Chlorphenesin IP/BP, which is anti-fungal, and Melitracen Hcl, which is an antidepressant. The firm has manufacturing facilities in India which cater to both domestic and international markets.

Frequently asked questions about Gennex Laboratories

Converted at the current exchange rate, the Gennex Laboratories share trades at 0.09 EUR (9.97 INR).

The revenue of Gennex Laboratories is 1.73 B INR. This figure is based on current financial data and reflects the company's business performance.

The profit of Gennex Laboratories is 209.79 M INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Gennex Laboratories is currently 11.55. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Gennex Laboratories stock.

The price-to-sales ratio (P/S) of Gennex Laboratories is currently 1.40. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Gennex Laboratories stock.

The Eulerpool Quality Score for Gennex Laboratories is 6/10.

The ISIN of Gennex Laboratories is INE509C01026. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Gennex Laboratories is 531739.BO. The ticker symbol is used to trade Gennex Laboratories shares on the stock exchange.

Fair ValueTerminal
9.27 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
INR
Initial public offering
Feb 9, 1996
ISIN
INE509C01026
Cusip
Y2705F137
Market capitalization
2.42 B INRMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
14.58
P/B Ratio
1.09
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
7.89 %
Last updated Oct 9, 2026, 2:10 AM

Gennex Laboratories Peer Group

Gennex Laboratories FIGI

GLL:IN · BBG000GS9SD5GLL:IB · BBG000GS9SV5